News

Gilead Sciences has added another synthetic lethal asset to its oncology portfolio, agreeing to pay $80 million upfront to obtain global rights to a clinic-ready cancer therapy from China-based Genhouse Bio. Headquartered in Suzhou, Genhouse Bio has been advancing its...

Results from the Phase III KALOS and LOGOS trials evaluating AstraZeneca Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) in patients with uncontrolled asthma have been published in The Lancet Respiratory Medicine, reporting statistically significant and clinically meaningful improvements compared...

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive...

An aging population is reshaping medicine. Why pharma must redesign drug development, trials, and coverage strategies to meet the real needs of patients 65+. Some may think that seniors are aging out of the healthcare system, however it’s quite the...

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services (MICS), a division of Medicover, have entered into a Memorandum of Understanding (MOU) aimed at advancing multinational clinical trial services. The agreement brings together GCCL, a data-driven clinical trial services...

Novartis has started work on a $1.1 billion biomedical research facility in California, adding a major new pillar to its long-term US investment strategy. The San Diego biomedical R&D site is part of a wider $23 billion expansion programme...

Bristol Myers Squibb has entered a global agreement with Evinova to deploy AI-powered clinical development tools across its worldwide pipeline. The Bristol Myers Evinova partnership is designed to improve trial efficiency, reduce costs and support better decision-making throughout drug...